QuickView: New tool for a common problem

TearLab is commercialising an FDA-approved point-of-care (PoC) device to measure tear osmolarity in dry eye disease (DED) patients. DED symptoms account for one-third of all eye care visits. TearLab has shown revenue growth in the past two years, but continues to post losses due to slow product adoption. A Clinical Laboratory Improvement Amendments (CLIA) waiver, favourable economics and utility for eye doctors, together with a large potential market, point the way to TearLab reaching profitabil...